Cancers,
Journal Year:
2025,
Volume and Issue:
17(7), P. 1125 - 1125
Published: March 27, 2025
Background:
The
heterogeneity
of
sarcomas
and
resulting
distinct
sub-type
specific
characteristics,
their
high
recurrence
rates,
tendency
for
distant
metastasis,
continue
to
present
significant
challenges
providing
optimal
treatments.
Objective:
To
provide
a
comprehensive
review
current
literature
clinical
trials
in
gene
cell
therapies
sarcomas.
Methods:
A
search
was
conducted
utilizing
the
following
databases:
PubMed,
Medline,
Google
Scholar
clinicaltrials.gov.
Search
terms
included
"gene
therapy",
"cell
"NK
therapy,
"CAR-T
"virotherapy",
"sarcoma",
"solid
tumors".
Additional
sources
were
identified
through
manual
searching
references
relevant
studies.
No
language
restrictions
set.
NCT
number,
study
status,
condition,
phase
noted
trials.
Results:
There
are
only
three
that
have
been
approved
by
federal
regulatory
agency.
Rexin-G:
first
tumor-targeted
therapy
vector
designed
target
all
advanced
solid
malignancies,
including
chemo-refractory
osteosarcomas
soft
tissue
sarcomas,
Philippine
FDA
2007.
Gendicine
oncolytic
virus
intratumoral
delivery
China
2003.
Afami-cel,
an
innovative
chimeric
antigen
receptor
(CAR)
T
synovial
sarcoma
United
States
2024.
Other
promising
discussed
text.
Conclusions:
future
holds
great
promise,
as
research
moves
late-stage
development.
integration
into
standard
treatment
protocols
has
potential
significantly
improve
quality
life
outcomes
patients
with
this
rare
challenging
group
cancers.
Bionatura journal :,
Journal Year:
2025,
Volume and Issue:
2(1), P. 1 - 23
Published: Jan. 11, 2025
La
leucemia
linfocítica
aguda
(LLA)
es
un
tipo
de
cáncer
la
sangre
que
afecta
a
médula
ósea
y
sangre.
Aunque
quimioterapia
el
tratamiento
principal,
inmunoterapia
ha
surgido
como
una
alternativa
prometedora,
especialmente
para
pacientes
con
enfermedad
refractaria
o
recurrente.
utiliza
propio
sistema
inmunológico
del
cuerpo
combatir
cáncer.
Existen
diferentes
tipos
LLA,
los
anticuerpos
monoclonales
(Rituximab),
inhibidores
puntos
control
inmunitario
(anti-PD-1,
anti-PD-L1,
anti-CTLA-4)
terapia
células
CAR-T
(Tisagenlecleucel).
Estas
terapias
han
demostrado
ser
eficaces
en
tasas
remisión
superiores
al
80%
algunos
casos.
Sin
embargo,
aún
existen
desafíos
resistencia
tratamiento,
efectos
secundarios
alto
costo.
Las
investigaciones
futuras
se
centran
desarrollar
estrategias
superar
tumoral,
mejorar
eficacia
seguridad
las
inmunoterapias,
hacerlas
más
accesibles
pacientes.
combinación
inmunoterapias
integración
tradicional
son
áreas
investigación
activa.
A
pesar
desafíos,
ofrece
esperanza
resultados
LLA.
Palabras
claves:
Leucemia
aguda,
inmunoterapia,
monoclonales,
inmunitario,
CAR-T,
biespecíficos,
conjugados
anticuerpo-fármaco,
residual
mínima,
clasificación
Annals of Hematology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 17, 2025
Abstract
Refractory
Diffuse
Large
B-cell
Lymphoma
(DLBCL)
presents
a
major
therapeutic
challenge
due
to
its
resistance
standard
treatments.
Engineered
T-cells,
especially
Chimeric
Antigen
Receptor
(CAR)
have
shown
promise
in
overcoming
drug
resistance.
This
study
investigates
the
effectiveness
of
WEE1-engineered
T-cells
targeting
and
eliminating
refractory
DLBCL
vitro.
CAR
were
created
by
transducing
5th-generation
construct
designed
recognize
WEE1,
surface
antigen
commonly
found
on
cells.
The
cytotoxic
effect
engineered
was
tested
against
Rituximab-resistant
cells
(RR-NU-DUL-1).
Apoptosis
cell
cycle
evaluated
using
flow
cytometry.
Quantitative
Real-time
PCR
(RT-PCR)
used
measure
expression
BCL2,
CDK2.
results
showed
significant
increase
target
lysis,
apoptosis,
necrosis,
reduction
percentage
G2M
phase
cycle,
as
well
decrease
gene
level,
indicating
strong
anti-tumor
activity.
These
findings
suggest
that
T-cell
therapy
holds
great
for
treating
DLBCL,
offering
potential
path
clinical
application.
vitro
evaluation
highlights
targeted
treatment
strategy
emphasizing
their
applicability
ability
overcome
mechanisms
this
aggressive
lymphoma
subtype.
Cancer Medicine,
Journal Year:
2025,
Volume and Issue:
14(5)
Published: Feb. 27, 2025
ABSTRACT
Cell
therapy
based
on
chimeric
antigen
receptor
(CAR)
T
cells
has
represented
a
revolutionary
new
approach
for
treating
tumors,
especially
hematological
diseases.
Complete
remission
rates
(CRR)
>
80%–97%
and
50%–90%
overall
response
(ORR)
have
been
achieved
with
treatment
CAR‐T
in
patients
malignant
B‐cell
tumors
that
relapsed
or
are
refractory
to
previous
treatments.
Toxicity
remains
the
major
problem.
Most
treated
develop
high‐grade
cytokine
release
syndrome
(CRS)
immune
effector
cell‐associated
neurotoxicity
(ICANS).
However,
unprecedentedly
high
CRR
ORR
led
approval
of
six
cell
therapeutics
by
Food
Drug
Administration
(FDA)
European
Medicines
Agency
(EMA),
prompting
researchers
improve
existing
products
ones.
By
now,
around
1000
clinical
trials
registered
at
ClinicalTrials.gov
:
82%
diseases,
while
remaining
16%
solid
tumors.
As
result
this
increased
research,
an
enormous
amount
conflicting
information
accumulated
literature,
each
group
follows
its
manufacturing
protocols
performs
specific
vitro
testing.
This
review
aimed
combine
compare
preclinical
information,
highlighting
most
used
provide
comprehensive
overview
world
cells,
from
their
characterization.
The
focus
is
all
steps
process,
collection
patient
donor
blood
enrichment
activation
anti‐CD3/CD28
beads,
interleukin‐2
(IL‐2)
IL‐7
IL‐15
(induction
more
functional
memory
phenotype),
transfection
(viral
non‐viral
methods).
Automation
crucial
ensuring
standardized
final
product.
Cancers,
Journal Year:
2025,
Volume and Issue:
17(7), P. 1125 - 1125
Published: March 27, 2025
Background:
The
heterogeneity
of
sarcomas
and
resulting
distinct
sub-type
specific
characteristics,
their
high
recurrence
rates,
tendency
for
distant
metastasis,
continue
to
present
significant
challenges
providing
optimal
treatments.
Objective:
To
provide
a
comprehensive
review
current
literature
clinical
trials
in
gene
cell
therapies
sarcomas.
Methods:
A
search
was
conducted
utilizing
the
following
databases:
PubMed,
Medline,
Google
Scholar
clinicaltrials.gov.
Search
terms
included
"gene
therapy",
"cell
"NK
therapy,
"CAR-T
"virotherapy",
"sarcoma",
"solid
tumors".
Additional
sources
were
identified
through
manual
searching
references
relevant
studies.
No
language
restrictions
set.
NCT
number,
study
status,
condition,
phase
noted
trials.
Results:
There
are
only
three
that
have
been
approved
by
federal
regulatory
agency.
Rexin-G:
first
tumor-targeted
therapy
vector
designed
target
all
advanced
solid
malignancies,
including
chemo-refractory
osteosarcomas
soft
tissue
sarcomas,
Philippine
FDA
2007.
Gendicine
oncolytic
virus
intratumoral
delivery
China
2003.
Afami-cel,
an
innovative
chimeric
antigen
receptor
(CAR)
T
synovial
sarcoma
United
States
2024.
Other
promising
discussed
text.
Conclusions:
future
holds
great
promise,
as
research
moves
late-stage
development.
integration
into
standard
treatment
protocols
has
potential
significantly
improve
quality
life
outcomes
patients
with
this
rare
challenging
group
cancers.
